Trial reportExperimental and clinical psychopharmacology2014
Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.
Trial report in Experimental and clinical psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Antipsychotic medications for cocaine dependence.The Cochrane database of systematic reviews · 2016Pooled it
- Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Aripiprazole for cocaine abstinence: a randomized-controlled trial with ecological momentary assessment.Behavioural pharmacology · 2017Trial
- Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.Brain sciences · 2022Review
- Clinical neuropharmacology of cocaine reinforcement: A narrative review of human laboratory self-administration studies.Journal of the experimental analysis of behavior · 2022Review
- Confronting the challenge of failed translation in medications development for substance use disorders.Pharmacology, biochemistry, and behavior · 2021Article
- Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?Expert opinion on pharmacotherapy · 2021Review
- The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology · 2020Review
- Improving translation of animal models of addiction and relapse by reverse translation.Nature reviews. Neuroscience · 2020Review
- Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study.Drugs - real world outcomes · 2020Article
- Aripiprazole reduces liver cell division.PloS one · 2020Article
- The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats.BMC biotechnology · 2018Article
- Medications for substance use disorders (SUD): emerging approaches.Expert opinion on emerging drugs · 2017Review
- Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome.Scientific reports · 2017Article
- Effects of Acute and Chronic Treatments with Dopamine DThe Journal of pharmacology and experimental therapeutics · 2017Article
- Cocaine choice procedures in animals, humans, and treatment-seekers: Can we bridge the divide?Pharmacology, biochemistry, and behavior · 2015Review
- Use of Preclinical Drug vs. Food Choice Procedures to Evaluate Candidate Medications for Cocaine Addiction.Current treatment options in psychiatry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Aripiprazole is a partial agonist at dopamine (D2) and serotonin (5-HT1a) receptors and 5-HT2 antagonist. Because cocaine affects dopamine and serotonin, this study assessed whether aripiprazole could diminish the reinforcing efficacy of cocaine. Secondary aims evaluated aripiprazole on ad lib cigarette smoking and with a novel 40-hr smoking abstinence procedure. Adults with regular cocaine and cigarette use completed this inpatient double blind, randomized, placebo-controlled mixed-design study. A placebo lead-in was followed by randomization to aripiprazole (0, 2 or 10 mg/day/p.o.; n = 7 completed/group). Three sets of test sessions, each consisting of 3 cocaine sample-choice (i.e., self-administration) sessions and 1 dose-response session, were conducted (once during the lead-in and twice after randomization). Sample sessions tested each cocaine dose (0, 20 and 40 mg/70 kg, i.v.) in random order; subjective, observer-rated and physiologic outcomes were collected. Later that day, participants chose between the morning's sample dose or descending amounts of money over 7 trials. In dose response sessions, all doses were given 1 hr apart in ascending order for pharmacodynamic and pharmacokinetic assessment. Two sets of smoking topography sessions were conducted during the lead-in and after randomization; 1 with and 1 without 40 hr of smoking abstinence. Number of ad lib cigarettes smoked during non-session days was collected. Cocaine produced prototypic effects, but aripiprazole did not significantly alter these effects or smoking outcomes. The smoking abstinence procedure reliably produced nicotine withdrawal and craving and increased smoking modestly. These data do not support further investigation of aripiprazole for cocaine or tobacco use disorder treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.